As shown, among the surface markers tested by flow cytometry, DCIS.COM cells showed a significant reduction in surface expression of integrin αVβ3, β3, and α4 with BCL9-KD (P < 0.05) (Supplementary Fig. 6a). This evidence concerns the gene BCL9 and ductal breast carcinoma in situ.